Brokerages Expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to Announce -$0.31 Earnings Per Share

Equities research analysts predict that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will announce earnings of ($0.31) per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.34). BioCryst Pharmaceuticals posted earnings per share of ($0.19) during the same quarter last year, which would indicate a negative year over year growth rate of 63.2%. The business is expected to report its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year earnings of ($1.21) per share for the current fiscal year, with EPS estimates ranging from ($1.27) to ($1.14). For the next financial year, analysts expect that the company will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.35) to ($0.69). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.28) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.28). BioCryst Pharmaceuticals had a negative return on equity of 223.34% and a negative net margin of 472.12%. The business had revenue of $5.89 million for the quarter, compared to analysts’ expectations of $2.92 million.

BCRX has been the topic of several analyst reports. Piper Jaffray Companies set a $15.00 target price on BioCryst Pharmaceuticals and gave the company a “buy” rating in a report on Monday, April 22nd. HC Wainwright reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday, May 22nd. Jefferies Financial Group lowered their target price on BioCryst Pharmaceuticals from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 22nd. Barclays upped their target price on BioCryst Pharmaceuticals from $6.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 2nd. Finally, Zacks Investment Research raised BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 26th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. BioCryst Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $9.56.

In related news, insider Thomas R. Staab II sold 7,500 shares of the stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $8.81, for a total value of $66,075.00. Following the completion of the sale, the insider now directly owns 140,176 shares of the company’s stock, valued at approximately $1,234,950.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Thomas R. Staab II sold 9,000 shares of the stock in a transaction on Monday, May 6th. The shares were sold at an average price of $7.75, for a total value of $69,750.00. Following the completion of the sale, the chief financial officer now directly owns 140,426 shares of the company’s stock, valued at $1,088,301.50. The disclosure for this sale can be found here. Insiders sold a total of 75,000 shares of company stock valued at $583,298 over the last three months. 5.20% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCRX. RA Capital Management LLC raised its holdings in BioCryst Pharmaceuticals by 15.4% during the fourth quarter. RA Capital Management LLC now owns 10,660,349 shares of the biotechnology company’s stock worth $86,029,000 after purchasing an additional 1,425,657 shares in the last quarter. FMR LLC boosted its position in shares of BioCryst Pharmaceuticals by 15.9% during the first quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock valued at $28,229,000 after purchasing an additional 475,989 shares in the last quarter. Federated Investors Inc. PA boosted its position in shares of BioCryst Pharmaceuticals by 78.7% during the first quarter. Federated Investors Inc. PA now owns 779,406 shares of the biotechnology company’s stock valued at $6,344,000 after purchasing an additional 343,269 shares in the last quarter. Emory University purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth $2,564,000. Finally, Bank of New York Mellon Corp raised its stake in shares of BioCryst Pharmaceuticals by 29.0% in the fourth quarter. Bank of New York Mellon Corp now owns 543,026 shares of the biotechnology company’s stock worth $4,383,000 after purchasing an additional 122,201 shares during the last quarter. 91.98% of the stock is owned by institutional investors and hedge funds.

BCRX stock traded down $0.10 during trading on Wednesday, hitting $3.52. The company had a trading volume of 37,102 shares, compared to its average volume of 2,804,299. The stock has a 50-day moving average price of $4.66. BioCryst Pharmaceuticals has a one year low of $2.80 and a one year high of $9.95. The firm has a market cap of $399.32 million, a PE ratio of -3.61 and a beta of 2.14. The company has a debt-to-equity ratio of 2.38, a quick ratio of 1.76 and a current ratio of 1.77.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Featured Story: What is a Real Estate Investment Trust (REIT)?

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.